Bordetella pertussis nucleic acid detection kit

By designing a combination of primer probes targeting ptxP and IS481 genes, combining the internal reference gene β-globin, and optimizing the PCR reaction solution, the sensitivity and specificity of Bacillus pertussis detection was solved, and rapid and accurate diagnosis was achieved, suitable for diseases Screening and clinical diagnosis.

CN118957119AActive Publication Date: 2024-11-15AUTOBIO DIAGNOSTICS CO LTD

Patent Information

Application Number
CN202411401073.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-09
Publication Date
2024-11-15
Estimated Expiration
2044-10-09

AI Technical Summary

Technical Problem

The existing Bacillus pertussis detection methods have problems such as low sensitivity, poor specificity, long experimental cycle and easy missed diagnosis. Especially bacterial methods and serological tests, which are difficult to accurately diagnose early onset, and are prone to false positives and affect treatment.

Method used

A primer probe combination was designed to target ptxP gene and IS481 gene fragments, and was detected by PCR technology, combining the internal reference gene β-globin, optimize the primer and probe sequences, improve the sensitivity and specificity of the detection, and reduce false positives. result.

Benefits of technology

It has achieved high sensitivity and specific detection of Bacillus pertussis, with the lower limit of detection up to 1.0CFU/mL, shortening the detection time, improving the detection efficiency, avoiding false positive results, and suitable for disease screening and clinical diagnosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005075283780000051
    Figure BDA0005075283780000051
  • Figure BDA0005075283780000061
    Figure BDA0005075283780000061
  • Figure BDA0005075283780000062
    Figure BDA0005075283780000062
Patent Text Reader

Abstract

The invention relates to the technical field of biological detection, in particular to a bordetella pertussis nucleic acid detection kit. The bordetella pertussis is determined by adopting ptxP alone or in combination with IS481, and the bordetella pertussis has no cross reaction with pathogens causing similar symptoms of pertussis. Meanwhile, the kit has the advantages of high sensitivity, strong specificity and the like, detection can be completed in only 50 min, and the lowest detection limit can reach 1 CFU / mL. The method is suitable for disease screening and clinical diagnosis, the detection time can be greatly shortened, the detection efficiency is improved, meanwhile, false positive results are avoided, and the method has important significance in disease monitoring, disease screening, clinical diagnosis and symptomatic treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biological detection technology, in particular to a Bordetella pertussis nucleic acid detection kit. Background Art

[0002] Pertussis is a severe acute respiratory infectious disease caused by Bordetella pertussis. Currently, bacteriology, serology and PCR techniques are mainly used to detect Bordetella pertussis.

[0003] The bacteriological method has a long experimental cycle and low sensitivity, only 12% to 60%, which is affected by the patient's age, vaccination status and course of the disease; serological testing is not sensitive within two weeks of onset, and it is easy to miss the best treatment period, and it is not suitable for infants (with maternal antibodies) and those who have been vaccinated with pertussis vaccine within 1 year; and the isolation and culture of Bordetella pertussis is difficult and the culture cycle is long. These factors have led to the seldom application of these two methods in clinical practice. In addition to Bordetella pertussis infection, Bordetella parapertussis, Bordetella bronchiseptica, Bordetella hohnii, etc. can all cause spasmodic coughs, which are similar to pertussis symptoms and difficult to identify. The nucleic acid amplification method is short in time, sensitive and specific, and can quickly diagnose pertussis in the early stage of the disease. It has become the best detection method for laboratory diagnosis.

[0004] The target gene sequence of Bordetella used more often in the diagnosis of pertussis at home and abroad is mainly the repeated insertion sequence IS481 (insertion sequences), which has 50 to 238 copies in the pathogen and has a very high detection sensitivity. However, this target gene exists in both Bordetella bronchiseptica and Bordetella hohnii, which can easily cause false positives and lead to misdiagnosis. Therefore, a sensitive and specific molecular diagnostic method is urgently needed for the differential diagnosis of Bordetella pertussis. Summary of the invention

[0005] In view of this, the technical problem to be solved by the present invention is to provide a Bordetella pertussis nucleic acid detection kit.

[0006] The present invention provides a primer-probe combination, wherein the targeting fragment includes a ptxP gene fragment, and the ptxP gene fragment has a nucleotide sequence as shown in SEQ ID NO:27.

[0007] Furthermore, the targeting fragment also includes an IS481 gene fragment, and the IS481 gene fragment has a nucleotide sequence as shown in SEQ ID NO:29.

[0008] The present invention screens and optimizes the targeting segment of the primer-probe combination;

[0009] In the embodiments of the present invention, the screening of targeted fragment gene combinations and the screening of specific gene targeted fragments are included; in the specific embodiments of the present invention, the targeted fragments are screened, and the results show that the detection of pertussis using the ptxP gene fragment with the nucleotide sequence shown in SEQ ID NO:27 has high detection sensitivity and a detection limit of 1.0 CFU / mL, while other targeted fragments targeting the ptxP gene have low sensitivity and poor detection specificity; the ptxP gene fragment with the nucleotide sequence shown in SEQ ID NO:27 is combined with the IS481 gene fragment as shown in SEQ ID NO:29 as a targeting fragment, and the detection results of the combination of other gene segments as targeting segments are more accurate, with lower false positives and more stable detection results.

[0010] The present invention combines the IS481 gene fragment shown in SEQ ID NO: 29 and the ptxP gene fragment shown in SEQ ID NO: 27 as target segments for the detection of pertussis, and the detection result has high specificity and is more accurate.

[0011] Furthermore,

[0012] The primer-probe combination of the present invention includes a primer-probe combination targeting a ptxP gene fragment and / or a primer-probe combination targeting an IS481 gene fragment;

[0013] The primer-probe combination targeting the ptxP gene fragment (SEQ ID NO: 27) includes an upstream primer of the nucleotide sequence shown in SEQ ID NO: 7, a downstream primer of the nucleotide sequence shown in SEQ ID NO: 8, and a probe of the nucleotide sequence shown in SEQ ID NO: 9;

[0014] The primer-probe combination targeting the IS481 gene fragment (SEQ ID NO:29) includes an upstream primer of the nucleotide sequence shown in SEQ ID NO:13, a downstream primer of the nucleotide sequence shown in SEQ ID NO:14, and a probe of the nucleotide sequence shown in SEQ ID NO:15.

[0015] In a specific embodiment of the present invention, β-globin is used as an internal reference gene, and the primer-probe combination of the present invention further includes a primer set and a probe targeting the internal reference gene;

[0016] The primer set and probe targeting the internal reference gene include: an upstream primer of the nucleotide sequence shown in SEQ ID NO:32, a downstream primer of the nucleotide sequence shown in SEQ ID NO:33, and a probe of the nucleotide sequence shown in SEQ ID NO:34.

[0017] Furthermore,

[0018] In the primer-probe combination,

[0019] The 5' end of each probe is coupled to a fluorescent group, and the 3' end is coupled to a fluorescent quenching group;

[0020] The fluorescent group is selected from any one of FAM, HEX, VIC, CY5 or ROX;

[0021] The fluorescence quenching group is selected from any one of BHQ1, MGB, MGB, BHQ2 or TAMRA.

[0022] The present invention screened the primer-probe combination. In some embodiments of the present invention, an upstream primer for the IS481 gene fragment with a nucleotide sequence as shown in SEQ ID NO:13, a downstream primer for the IS481 gene fragment with a nucleotide sequence as shown in SEQ ID NO:14, and a probe for the IS481 gene fragment with a nucleotide sequence as shown in SEQ ID NO:15, as well as an upstream primer for the ptxP gene fragment with a nucleotide sequence as shown in SEQ ID NO:7, a downstream primer for the ptxP gene fragment with a nucleotide sequence as shown in SEQ ID NO:8, and a probe for the ptxP gene fragment with a nucleotide sequence as shown in SEQ ID NO:9 were used. The test results showed that the primer-probe combination of the present invention has a better detection effect on clinical positive samples of pertussis.

[0023] The present invention provides the use of the primer-probe combination in preparing a pertussis detection product.

[0024] The present invention provides a kit for pertussis detection, which comprises at least one of PCR reaction solution 1 and / or PCR reaction solution 2 and the primer-probe combination of the present invention.

[0025] Furthermore, the kit of the present invention further comprises: template DNA, dNTPs, DNA polymerase, uracil glycosylase, a positive reference substance, a negative reference substance or a blank control substance.

[0026] In the kit of the present invention,

[0027] The PCR reaction solution 1 includes 1M-3M betaine, 1vt%-3vt% formamide, 10mM-20mM ammonium sulfate, 0.05vt%-0.2vt% Tween-20, 10mM-30mM tetramethylammonium chloride, and 8vt%-12vt% polyethylene glycol;

[0028] The PCR reaction solution 2 includes 2mM-6mM magnesium chloride solution and 2mM-6mM manganese acetate solution;

[0029] The template DNA is used at a concentration of 10 ng / μL to 100 ng / μL;

[0030] The dNTPs are used at a concentration of 0.02 mM to 0.06 mM;

[0031] The DNA polymerase is used at a concentration of 0.1U / μL to 0.3U / μL;

[0032] The concentration of the uracil glycosylase is 0.05U / μL to 0.15U / μL;

[0033] The primers are used at a concentration of 0.6 μmolL to 1 μmolL;

[0034] The probe is used at a concentration of 0.2 μmoL to 0.6 μmoL.

[0035] Furthermore,

[0036] In a specific embodiment of the present invention,

[0037] The PCR reaction solution 1 includes 2M betaine, 2vt% formamide, 15mM ammonium sulfate, 0.15vt% Tween-20, 20mM tetramethylammonium chloride and 10vt% polyethylene glycol; in a specific embodiment of the present invention, the amount of the PCR reaction solution 1 added to the reaction system is 15μl / 50μl;

[0038] The PCR reaction solution 2 includes 4 mM magnesium chloride and 4 mM manganese acetate; in a specific embodiment of the present invention, the amount of the PCR reaction solution 2 added to the reaction system is 15 μl / 50 μl;

[0039] The template DNA is used at a concentration of 10 ng / μL to 100 ng / μL;

[0040] The dNTPs were used at a concentration of 0.04 mM;

[0041] The concentration of the DNA polymerase used is 0.2U / μL;

[0042] The concentration of uracil glycosylase used is 0.1 U / μL

[0043] The primers were used at a concentration of 0.8 μmol;

[0044] The probe was used at a concentration of 0.4 μmol

[0045] The positive reference is a culture of Bordetella pertussis;

[0046] The negative reference is a Bordetella pertussis negative clinical sample;

[0047] The blank control was nuclease-free water.

[0048] The present invention provides a non-diagnostic method for detecting pertussis, which comprises detecting a sample using at least one of the following A) to B):

[0049] A), the primer-probe combination of the present invention;

[0050] B), the kit of the present invention.

[0051] The non-diagnostic pertussis detection method of the present invention comprises the following steps: after obtaining the sample nucleic acid, determining whether the patient suffers from pertussis according to the detection result.

[0052] Furthermore,

[0053] The criteria for determination are:

[0054] The Ct of the internal reference gene was ≤35 and the Ct of the ptxP gene was ≤38, which was judged as positive for Bordetella pertussis;

[0055] The Ct of the internal reference gene ≤ 35, the Ct of the ptxP gene > 38 or No CT, and the Ct of the IS481 gene ≤ 38 were judged as negative for Bordetella pertussis and positive for Bordetella hohnii / Bordetella bronchiseptica;

[0056] The Ct of the internal reference gene ≤ 35, the Ct of the ptxP gene > 38 or No CT, and the Ct of the IS481 gene > 38 or No CT were judged as negative for Bordetella pertussis / Bordetella hohnii / Bordetella bronchiseptica;

[0057] If the Ct of the internal reference gene is greater than 35 or there is no CT, the sample is invalid and resampling is recommended.

[0058] The detection procedure is: 50°C, 2 min; 95°C, 2 min; 95°C, 10 sec, 45 cycles; 60°C, 22 sec, collecting fluorescence signals.

[0059] Furthermore, the samples described in the present invention include nasopharyngeal swabs, saliva, blood, nasopharyngeal / oropharyngeal saline washes or aspirates, deep cough sputum, bronchial lavage fluid, alveolar lavage fluid and / or deep throat saliva, etc., and the present invention is not limited to this;

[0060] The internal reference gene is a human endogenous substance (β-globin), so there is no need to operate the internal reference nucleic acid extraction. The sample comes with the internal reference when operating, and no additional processing is required.

[0061] The non-diagnostic pertussis detection method described in the present invention can be used for scientific research purposes and as a medium in the development of other pertussis detection reagents, kits, detection techniques and / or equipment, and the present invention is not limited to this.

[0062] The present invention uses ptxP alone or in combination with IS481 to identify Bordetella pertussis, and has no cross-reaction with pathogens that cause similar symptoms to pertussis. It also has the advantages of high sensitivity and strong specificity, and PCR amplification can be completed in only 50 minutes, with a minimum detection limit of 1 CFU / mL. It is suitable for disease screening and clinical diagnosis, can greatly shorten the detection time, improve detection efficiency, and avoid false positive results, which is of great significance in disease monitoring, disease screening, clinical diagnosis and symptomatic treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0063] Figure 1 Shows the PCR amplification curve in ion concentration screening;

[0064] Figure 2 Evaluation of the detection specificity of the test kit;

[0065] Figure 3 The stability evaluation of the test kit was shown. DETAILED DESCRIPTION

[0066] The present invention provides a nucleic acid detection kit for Bordetella pertussis, and those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve it. It is particularly important to point out that all similar replacements and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The methods and applications of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications of this article without departing from the content, spirit and scope of the present invention to realize and apply the technology of the present invention.

[0067] Internal reference gene human β-globin target segment: cacctgactcctgaggagaagtctgccgttactgccctgtggggcaaggtgaacgtggatgaagttggtggtgaggccctgggcaggttggtatcaaggttacaagacaggtttaaggagaccaa tagaaactgggcatgtggagacagagaagactcttgggtttctgataggcactgactctctctgcctattggtctattttcccacccttaggctgctggtggtctacccttggacccggaggttctttgagtcct(SEQ ID NO:31);

[0068] Internal reference gene upstream primer: gccctgggcaggttggtat (SEQ ID NO: 32);

[0069] Internal reference gene downstream primer: tctccacatgcccagttt (SEQ ID NO: 33);

[0070] Internal reference gene probe: caggtttaaggagacca (SEQ ID NO: 34);

[0071] Real-time fluorescence quantitative PCR: A method that uses fluorescent chemicals to measure the total amount of products after each polymerase chain reaction (PCR) cycle in a DNA amplification reaction. A method that uses internal or external reference methods to quantitatively analyze specific DNA sequences in the sample to be tested.

[0072] Minimum detection limit: The kit can stably detect the lowest concentration of a specific nucleic acid fragment in a sample with a 95% detection rate.

[0073] Copy number: refers to the number of a gene (which can be a plasmid) in the genome of a certain organism. Single copy means that there is only one copy of the gene in the genome of the organism, while multiple copies means that there are multiple copies.

[0074] CFU: (colony forming units) refers to each colony formed on the agar plate after cultivation at a certain temperature and time. It is the unit for calculating the number of bacteria or molds.

[0075] Serological testing: Use immune serum (diagnostic serum) containing known specific antibodies to undergo serological reaction with antigens in isolated and cultured unknown pure bacteria or specimens to determine the species or type of the pathogen.

[0076] Tm value: Melting temperature (Tm) refers to the temperature at which the absorbance value increases to half of the maximum value, which is called the melting temperature or melting point of DNA.

[0077] The test materials used in the present invention are all common commercial products and can be purchased on the market. The present invention is further described below in conjunction with the embodiments:

[0078] Example 1 Screening of target segments

[0079] All genome sequences of Bordetella pertussis, Bordetella hodgensis, Bordetella parapertussis, and Bordetella bronchiseptica were downloaded from Genbank, and multiple alignments were performed using MEGA6 software to find the differential segments of the genomes of the above pathogens. Finally, the stable conservative regions of the Bordetella pertussis genome sequence, IS481 and ptxP, were determined as the target sequences for detection, and specific primers and probes were designed for the conservative regions of these two target genes. When designing, attention should be paid to the small difference in Tm values ​​between primers, and the Tm value of the probe should be slightly higher than that of the primer. The GC content should be moderate, between 40% and 60%. Try to avoid the formation of primer secondary structure, prevent primer interaction, and avoid the formation of hairpin structure. At the same time, it is necessary to achieve no cross-reaction between primer pairs and fully ensure the specificity of primer amplification.

[0080] 1. Screening of Bordetella pertussis ptxP target segment

[0081] Through gene sequence alignment and analysis, three relatively conservative ptxP target segments were screened out, and primers and probes were subsequently designed for verification. The specific groupings are shown in Table 1.

[0082] To evaluate the specificity of the above three target segments in detecting Bordetella pertussis, the three groups shown in Table 1 were used to detect Bordetella pertussis, Bordetella parapertussis, Bordetella hohnii, and Bordetella bronchiseptica, which are related to human infection in the genus Bordetella, and the test results are shown in Table 2.

[0083] The evaluation results in Table 2 show that target segments 1 and 2 have overlaps with Bordetella parapertussis and Bordetella bronchiseptica, while target segment 3 (SEQ ID NO: 27) has no overlaps with Bordetella parapertussis, Bordetella hohnii, and Bordetella bronchiseptica, and has the best specificity.

[0084] Table 1. ptxP target sequences and primer probes

[0085]

[0086]

[0087] Table 2. Specificity of the three target segments of ptxP for detecting Bordetella pertussis

[0088] Experimental Group Bordetella pertussis Bordetella parapertussis Bordetella hohnii Bordetella bronchiseptica 1 ﹢ ﹢ - ﹢ 2 ﹢ ﹢ - ﹢ 3 ﹢ - - -

[0089] Note: “-” means the pathogen is negative; “+” means the pathogen is positive;

[0090] 2. Screening of Bordetella pertussis IS481 target segment

[0091] By comparing and analyzing the genome sequences and IS481 gene sequences of Bordetella pertussis, Bordetella hohnii, Bordetella parapertussis, and Bordetella bronchiseptica, three relatively conservative IS481 target segments were screened out, and then primers and probes were designed for verification. The specific grouping is shown in Table 3.

[0092] To evaluate the sensitivity of the above three target segments in detecting Bordetella pertussis, Bordetella pertussis suspensions with known concentrations (1×10 7 CFU / ml) were diluted to 100 CFU / ml, 10 CFU / ml, 1 CFU / ml, 0.5 CFU / ml, and 0.25 CFU / ml, respectively, and then detected using the three sets of primers and probes shown in Table 3. The test results are shown in Table 4.

[0093] The evaluation results in Table 4 show that the sensitivity of target segment 1 and target segment 3 in detecting Bordetella pertussis is lower than that of target segment 2, and the Ct value of target segment 2 (SEQ ID NO: 29) is the smallest and its sensitivity is the best.

[0094] Table 3. IS481 target sequence and primer probe

[0095]

[0096]

[0097] Table 4. Sensitivity of three target segments of IS481 in detecting Bordetella pertussis

[0098]

[0099] Example 2 Optimization of primers and probes for target segments

[0100] 1. Design and screening of primers and probes

[0101] Multiple sets of primer-probe combinations were designed for IS481 (SEQ ID NO: 29) and ptxP (SEQ ID NO: 27), and two representative sets were taken as examples. The specific sequences are shown in Table 5. The designed primer-probes were verified using pertussis clinical positive samples, and the test results are as follows:

[0102] Table 5. Primer probe screening using IS481 and ptxP as target sequences for detection

[0103]

[0104]

[0105] Many attempts were made during the experiment. This table takes Group 1 and Group 2 as examples. The experimental results show that compared with Group 2 and other groups, Bordetella pertussis IS481 combination 1 and Bordetella pertussis ptxP combination 1 are better in detecting clinically positive pertussis samples. Therefore, this kit selects the primer probe of combination 1 as the final solution.

[0106] 2. Sample processing and nucleic acid extraction

[0107] Add 1 mL of normal saline to the collected nasopharyngeal swab sample, shake it thoroughly to mix, take 200 μL of the sample, and use the magnetic bead method to extract nucleic acid (nucleic acid extraction and purification reagents from Zhengzhou Antu Bioengineering Co., Ltd., Yu Zheng Xie Bei No. 20180037).

[0108] 3. Prepare the reaction system

[0109] A 50 μL reaction system was used to amplify the nucleic acid of the above-extracted pertussis rod clinical sample (the sample contained an internal standard gene and no additional addition was required), which included PCR reaction solution 1 (containing 2M betaine, 2vt% formamide, 15mM ammonium sulfate, 0.15vt% Tween-20, 20mM tetramethylammonium chloride, 10vt% polyethylene glycol, and the concentrations here are the concentrations at the time of use), 0.04mM dNTPs, 0.2U / μL DNA polymerase, 0.1U / μL uracil glycosylase, PCR reaction solution 2 (4mM magnesium chloride solution, 4mM manganese acetate solution, and the concentrations here are the concentrations at the time of use), each primer concentration was 0.8μmoL, each probe concentration was 0.4μmoL, and then 15μL of the extracted nucleic acid was added, and the rest was supplemented to 50μL with ddH2O. The above reagent components were added to the PCR tube for the following reactions: the first stage: 50°C, 2 min; the second stage: 95°C, 2 min; the third stage: 95°C, 10 sec; 60°C, 22 sec. There were 45 cycles in the third stage, and the fluorescence signal was collected at 60°C. Finally, the results were interpreted by observing the fluorescence curve and Ct value generated during the reaction. The criteria for the interpretation of the results were:

[0110] The Ct of the internal reference gene was ≤35 and the Ct of the ptxP gene was ≤38, which was judged as positive for Bordetella pertussis;

[0111] The Ct of the internal reference gene ≤ 35, the Ct of the ptxP gene > 38 or No CT, and the Ct of the IS481 gene ≤ 38 were judged as negative for Bordetella pertussis and positive for Bordetella hohnii / Bordetella bronchiseptica;

[0112] The Ct of the internal reference gene ≤ 35, the Ct of the ptxP gene > 38 or No CT, and the Ct of the IS481 gene > 38 or No CT were judged as negative for Bordetella pertussis / Bordetella hohnii / Bordetella bronchiseptica;

[0113] If the Ct of the internal reference gene is greater than 35 or there is no CT, the sample is invalid and resampling is recommended.

[0114] The results are as follows Figure 1 As shown, this sample is positive for Bordetella pertussis.

[0115] Example 3 Optimization and screening of PCR reaction solution

[0116] 1. Screening of Tween-20 concentration in PCR reaction solution 1

[0117] Tween-20 is a nonionic surfactant that can increase the stability of the PCR reaction system. It is widely used in PCR amplification systems by reducing surface tension, maintaining the uniformity of the reaction solution, reducing the secondary structure of DNA, and protecting the activity of the polymerase. This study screened different concentrations of Tween-20 and verified the effects of 0.05vt%, 0.1vt%, 0.15vt%, and 0.2vt% of Tween-20 on PCR amplification efficiency. Four pertussis positive samples and one negative sample were tested at different concentrations. The concentrations of positive clinical samples 1-4 were 1×10 5 CFU / ml, 1×10 4 CFU / ml, 1×10 3 CFU / ml, 1×10 2 CFU / ml, each test was repeated 3 times. The Ct value of positive samples was compared. The smaller the Ct value, the better the amplification ability. The results are shown in Table 6:

[0118] Table 6. Screening and validation of different concentrations of Tween-20

[0119]

[0120] The validation results showed that 0.05vt% to 0.2vt% Tween-20 can achieve accurate detection of pertussis. 0.15vt% Tween-20 has the smallest Ct value when detecting pertussis positive samples, which means the amplification efficiency is the highest.

[0121] 2. Betaine concentration screening in PCR reaction solution 1

[0122] Betaine is a PCR enhancer suitable for amplifying templates with high GC content and complex secondary structures. Excessive use will inhibit the PCR reaction. This study screened different concentrations of betaine and verified the effects of 1M, 2M and 3M betaine on PCR amplification efficiency. Four pertussis positive samples and one negative sample were tested at different concentrations. The concentrations of positive clinical samples 1-4 were 1×10 5CFU / ml, 1×10 4 CFU / ml, 1×10 3 CFU / ml, 1×10 2 CFU / ml, each test was repeated 3 times. The positive samples were compared with the Ct value. The smaller the Ct value, the better the amplification ability. The results are shown in Table 7:

[0123] Table 7. Screening validation of different concentrations of betaine

[0124]

[0125] The validation results showed that 1M to 3M betaine can achieve accurate detection of pertussis. 2M betaine had the smallest Ct value when detecting pertussis-positive samples, which means the amplification efficiency was the highest.

[0126] 3. Screening of 2 ion concentrations in PCR reaction solution

[0127] The main component of PCR reaction solution 2 is Mn 2+ and Mg 2+ The experiment found that compared with using Mg alone, 2+ As compared with PCR reaction solution 2, Mn 2+ and Mg 2+ Mixing in equal proportions can increase the amplification height of this kit by about 20%; then mixing in equal proportions of Mn 2+ and Mg 2+ The effect of Mn concentration on PCR reaction was investigated, and the concentrations of 2mM, 3mM, 4mM, 5mM, and 6mM were compared. 2+ and Mg 2+ Concentration, 4 pertussis positive samples and 1 negative sample with different concentrations were tested, among which the concentrations of positive clinical samples 1-4 were 1×10 5 CFU / ml, 1×10 4 CFU / ml, 1×10 3 CFU / ml, 1×10 2 CFU / ml, each test was repeated 3 times. The test result of the positive sample should be the normal value of the target Ct, and the test result of the negative sample should be the target NoCt, which meets the expected requirements. The positive samples are compared with the Ct value. The smaller the Ct value, the better the amplification ability. The results are shown in Table 8.

[0128] The evaluation results in Table 8 show that the test results of positive and negative samples of the five ion concentrations all meet the requirements. 2+ and Mg 2+ The overall Ct mean value is the smallest at a concentration of 4 mM. 2+ and Mg 2+The concentration was selected to be 4 mM and mixed in equal proportions as PCR reaction solution 2.

[0129] Table 8. Ion concentration screening results

[0130]

[0131]

[0132] Example 4 Kit Performance Evaluation

[0133] 1. Evaluation of kit detection specificity

[0134] Table 9. Kit detection specificity

[0135] Pathogens concentration Judgment result Bordetella pertussis <![CDATA[4.25×10 5 CFU / mL]]> Positive Bordetella hohnii <![CDATA[3.6×10 7 CFU / mL]]> Negative Streptococcus pneumoniae <![CDATA[3.8×10 6 CFU / mL]]> Negative Bordetella parapertussis <![CDATA[8.0×10 7 CFU / mL]]> Negative Bordetella bronchiseptica <![CDATA[7.1×10 7 CFU / mL]]> Negative Influenza A virus <![CDATA[4.54×10 6 copies / mL]]> Negative Influenza B virus <![CDATA[4.59×10 6 copies / mL]]> Negative Mycoplasma pneumoniae <![CDATA[4.39×10 6 copies / mL]]> Negative Chlamydia pneumoniae <![CDATA[5.02×10 6 copies / mL]]> Negative Respiratory syncytial virus <![CDATA[6.22×10 6 copies / mL]]> Negative Parainfluenza virus <![CDATA[7.32×10 6 copies / mL]]> Negative Human metapneumovirus <![CDATA[3.67×10 6 copies / mL]]> Negative

[0136] In order to evaluate the detection specificity of the kit provided by the present invention, a group of common respiratory pathogens that cause symptoms such as cough were screened from clinical samples, such as Mycoplasma pneumoniae, Chlamydia trachomatis, Streptococcus pneumoniae, influenza A virus, influenza B virus, respiratory syncytial virus, parainfluenza virus, human metapneumovirus, Bordetella pertussis and Bordetella bronchiseptica with high homology (concentrations are shown in Table 9). The above pathogens were extracted with nucleic acids by magnetic beads and then tested using the kit of the present invention. The results are as follows: Figure 2 As shown: only Bordetella pertussis samples have an amplification curve, and the other pathogens have no amplification and no jump. The evaluation results show that this kit has excellent specificity and no cross-talk or interference with common respiratory pathogens.

[0137] 2. Evaluation of kit detection sensitivity

[0138] Bordetella pertussis isolated from pertussis-positive clinical samples was selected, and after culture and activation, a Bordetella pertussis bacterial solution was prepared, and the bacterial solution was inactivated and the colony count was performed using turbidimetry. Subsequently, bacterial suspensions of 100, 10, 1, 0.5, and 0.25 CFU / mL were prepared respectively, and the nucleic acid of the above samples was extracted using the magnetic bead method, and the extracted nucleic acid was added to the PCR amplification system for reaction. The amplification results are shown in Table 10:

[0139] Table 10. Detection sensitivity of the kit

[0140]

[0141] The evaluation results showed that the minimum detection limit of this kit for Bordetella pertussis was 1 CFU / mL.

[0142] 3. Evaluation of kit detection stability

[0143] In order to evaluate the stability of the kit provided by the present invention, the PCR reaction solution was placed in a 37°C incubator for 7, 14, and 21 days, and then the pertussis-positive clinical samples were tested and compared with the untreated reagent. The amplification curves are shown in FIG. Figure 3 shown.

[0144] The evaluation results show that the kit provided by the present invention detects common respiratory pathogens with negative results; the results of detecting Bordetella parapertussis, Bordetella hohnii, and Bordetella bronchiseptica, which have high homology with Bordetella pertussis, are also negative. The above results show that the primers and probes used in the method established by the present invention have strong specificity and do not cross-react with other pathogens. Under the storage condition of 37°C, the kit can still detect Bordetella pertussis normally after 21 days of storage, and the stability is excellent.

[0145] The present invention selects a ptxP gene fragment with a nucleotide sequence as shown in SEQ ID NO:27 to detect pertussis, and the detection sensitivity is high, and the detection limit can reach 1.0 CFU / mL; the ptxP gene fragment is combined with the IS481 gene fragment with a nucleotide sequence as shown in SEQ ID NO:29, and the primer probe combination and the reagent components are optimized, and the detection result has no crossover with Bordetella parapertussis, Bordetella bronchiseptica, and Bordetella hohenryi, and the specificity is extremely strong, and the sensitivity and specificity of Bordetella pertussis detection can be significantly improved, and the operation is simple, the cost is low, and the detection can be completed in only 50 minutes, which is suitable for disease screening and clinical diagnosis, greatly shortens the detection time, improves the detection efficiency, and avoids false positive results, which is of great significance in disease monitoring, disease screening, clinical diagnosis and symptomatic treatment.

[0146] The above are only preferred embodiments of the present invention. It should be pointed out that, for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A primer-probe combination, characterized in that: The targeting fragment includes a ptxP gene fragment having a nucleotide sequence as shown in SEQ ID NO:

27.

2. The primer-probe combination according to claim 1, characterized in that: The targeting fragment includes an IS481 gene fragment, and the IS481 gene fragment has a nucleotide sequence as shown in SEQ ID NO:

29.

3. The primer-probe combination according to claim 1 or 2, characterized in that: A primer-probe combination targeting a ptxP gene fragment and / or a primer-probe combination targeting an IS481 gene fragment; The primer-probe combination targeting the ptxP gene fragment includes an upstream primer of the nucleotide sequence shown in SEQ ID NO:7, a downstream primer of the nucleotide sequence shown in SEQ ID NO:8, and a probe of the nucleotide sequence shown in SEQ ID NO:9; The primer-probe combination targeting the IS481 gene fragment includes an upstream primer with a nucleotide sequence as shown in SEQ ID NO:13, a downstream primer with a nucleotide sequence as shown in SEQ ID NO:14, and a probe with a nucleotide sequence as shown in SEQ ID NO:

15.

4. The primer-probe combination according to any one of claims 1 to 3, characterized in that: Primer sets and probes targeting an internal reference gene are also included.

5. The primer-probe combination according to any one of claims 1 to 4, characterized in that: The 5' end of each probe is coupled to a fluorescent group, and the 3' end is coupled to a fluorescent quenching group; The fluorescent group is selected from any one of FAM, HEX, VIC, CY5 or ROX; The fluorescence quenching group is selected from any one of BHQ1, MGB, MGB, BHQ2 or TAMRA.

6. Use of the primer-probe combination according to any one of claims 1 to 5 in the preparation of a pertussis detection product.

7. A kit for detecting pertussis, characterized in that: The method comprises at least one of PCR reaction solution 1 and / or PCR reaction solution 2 and the primer-probe combination according to any one of claims 1 to 5.

8. The kit according to claim 7, characterized in that The PCR reaction solution 1 includes 1M-3M betaine, 1vt%-3vt% formamide, 10mM-20mM ammonium sulfate, 0.05vt%-0.2vt% Tween-20, 10mM-30mM tetramethylammonium chloride and 8vt%-12vt% polyethylene glycol.

9. The kit according to claim 7 or 8, characterized in that The PCR reaction solution 2 includes a 2mM to 6mM magnesium chloride solution and a 2mM to 6mM manganese acetate solution.

10. A method for detecting pertussis for non-diagnostic purposes, characterized in that: The method comprises detecting the sample using at least one of the following A) to B): A), a primer-probe combination according to any one of claims 1 to 5; B) The kit according to any one of claims 7 to 9.

Citation Information

Patent Citations

  • DNA fragment, primer, probe and kit for detecting four kinds of abalone bacteria and specifically detecting pertussis abalone bacteria and application

    CN113718045A

  • Primer probe combination and kit for detecting respiratory pathogen nucleic acid

    CN117604132A

  • Reagent and kit for detecting bordetella pertussis and bordetella parapertussis

    CN118127194A

Cited By

  • Bordetella pertussis ptxP1 / ptxP3 genetic typing detection kit and detection method

    CN120400376A